Phase II study of liposomal doxorubicin in advanced gynecologic cancers

Gynecologic Oncology

Volumn 78, Issue 2, 2000, Pages 143-147

  Israel, Valerie P ^a   Garcia, Augustin A ^a   Roman, Linda ^a   Muderspach, Laila ^a   Burnett, Alexander ^a   Jeffers, Susan ^a   Muggia, Franco M ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; LIPOSOME; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG FORMULATION; DRUG RESISTANCE; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0033842471     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5819     Document Type: Article

References (20)

1. Cancer statistics
2. Adriamycin and bleomycin alone and in combination in gynecological cancers
3. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study
4. Doxorubicin in sterically stabilized liposomes
5. A retrospective analysis of the clinical utility of Doxil in recurrent ovarian cancer
6. Interim analysis of a non-comparative, multicenter study of Doxil/Caelyx in the treatment of patients with refractory ovarian cancer
7. Liposomal doxorubicin (Dox-SL): Antitumor activity and unique toxicities during two complementary phase I studies
8. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
9. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
10. Doxil in platinum-refractory epithelial ovarian cancer (EOC): Results from three consecutive phase I/II studies
11. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with ovarian cancer
12. A phase I study of topotecan, cisplatin and paclitaxel in newly diagnosed epithelial ovarian cancer: A Gynecologic Oncology Group study
13. A phase I study of paclitaxel, carboplatin, and increasing doses of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: A Gynecologic Oncology Group study
14. Phase I/II trial of paclitaxel (1-hour infusion), carboplatin and gemcitabine in the treatment of advanced non-small cell lung cancer
15. Impact of doxorubicin on survival in advanced ovarian cancer
16. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis
17. Doxil plus cisplatin: Combined results of two phase I studies
18. Phase I study of Doxil (liposomal doxorubicin) in combination with paclitaxel
19. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines
20. Prolonged infusion with Doxil: A well tolerated regimen